Please login to the form below

Not currently logged in
Email:
Password:

OncoVex

This page shows the latest OncoVex news and features for those working in and with pharma, biotech and healthcare.

AZ signs yet another cancer immunotherapy deal

AZ signs yet another cancer immunotherapy deal

The most advanced is Amgen's OncoVex (talimogene laherparepvec), which in 2013 became the first oncolytic virus to show efficacy in a phase III trial involving people with the skin cancer

Latest news

  • Amgen says viral melanoma therapy clears phase III trial Amgen says viral melanoma therapy clears phase III trial

    Amgen says viral melanoma therapy clears phase III trial. OncoVex demonstrates durable response in skin cancer patients. ... The melanoma immunotherapeutic - talimogene laherparepvec (also known as OncoVex) - works by introducing a virus that selectively

  • Disease focus: Melanoma

    nilotinib. In development. Vaccines. OncoVEX GM-CSF. In development. Vaccines. MAGE-A3 ASCI.

  • Amgen to buy BioVex

    BioVex's portfolio includes OncoVex (GM-CSF) – an investigational vaccine to treat melanoma and head and neck cancer. ... Philip Astley-Sparke, CEO, BioVex, also praised the agreement: "Amgen is ideally positioned to leverage the potential of OncoVEX

More from news
Approximately 1 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Life Healthcare Communications

Life is a creative communications agency offering multi-channel solutions for the healthcare industry. We use a storytelling approach to turn...

Latest intelligence

Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....
The rise of vertical integration in the US payer landscape
Is it a solution to addressing the challenges of the value-based marketplace?...
Light_bulb_Stock_Market.jpg
Creativity has lost its worth
Creativity has lost its worth, and sadly it is undermining effectiveness...

Infographics